Shield Therapeutics plc

STX · LSE · Healthcare / Drug Manufacturers - Specialty & Generic

3.20GBX-0.10 (-3.03%)

Price History

Full chart

Market Stats

Previous Close3.30

Open3.30

Day Range3.03 – 3.40

52-Week Range3.70 – 12.50

Volume1.50M

Market Cap60.15M

P/E (TTM)0.00

Forward P/E6.36

EPS-0.01

Dividend Yield0.00%

Beta1.73

50-Day Avg4.91

200-Day Avg7.42

About

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Karl Anders Lundstrom
Employees61
HeadquartersNorthern Design Centre, Gateshead, United Kingdom, NE8 3DF, UK
Websitehttps://www.shieldtherapeutics.com

Leadership

Mr. Karl Anders LundstromCEO & Director · b. 1962
Dr. Christian Karl Kurt Schweiger M.D., Ph.D.Co-Founder & Non Executive Director · b. 1966
Mr. Michael JensenChief Financial Officer
Ms. Lucy Kate Huntington-BaileyGeneral Counsel, Chief Compliance Officer & Company Secretary
Mr. David ChildsSenior VP of Manufacturing & Strategic Alliances
Ms. Carol AkinolaHead of Pharmacovigilance & Medical Information
Mr. Andrew HurleyChief Commercial Officer · b. 1969
Mr. Bryon KallertSenior Director of Financial Planning & Analysis

Financials

Income Statement

Currency: USD	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	-	244.00K	0	304.00K	637.00K	11.88M	719.00K	10.39M	1.52M	4.48M	16.54M	32.18M	50.74M
Growth (%)	-	-	-	-100.00%	-	+109.54%	+1765.15%	-93.95%	+1344.65%	-85.38%	+195.11%	+268.96%	+94.57%	+57.69%
Cost of Revenue	28.00K	32.00K	36.00K	50.00K	100.00K	155.00K	311.00K	485.00K	4.06M	3.19M	3.04M	11.45M	18.29M	28.36M
Gross Profit	-28.00K	-32.00K	-36.00K	-50.00K	204.00K	482.00K	11.57M	234.00K	6.33M	-1.67M	2.00M	5.09M	13.22M	22.38M
Gross Margin	-	-	-14.75%	-	67.11%	75.67%	97.38%	32.55%	60.92%	-109.81%	44.70%	30.78%	41.09%	44.11%
Operating Expense	3.78M	4.05M	3.60M	6.61M	12.66M	21.43M	16.74M	9.27M	8.48M	18.74M	28.39M	36.42M	36.10M	32.68M
Operating Income	-3.81M	-4.09M	-3.63M	-6.66M	-12.46M	-20.95M	-5.17M	-9.04M	-2.15M	-20.41M	-26.39M	-31.33M	-22.87M	-10.30M
Operating Margin	-	-	-1489.75%	-	-4098.68%	-3289.01%	-43.50%	-1256.61%	-20.74%	-1343.32%	-588.72%	-189.43%	-71.08%	-20.29%
EBITDA	-3.78M	-4.05M	-11.73M	-22.57M	-10.40M	-18.54M	-2.47M	-9.26M	820.00K	-17.69M	-46.07M	-38.28M	-21.26M	-9.16M
EBITDA Margin	-	-	-4809.02%	-	-3420.07%	-2910.52%	-20.78%	-1288.56%	7.89%	-1164.71%	-1027.65%	-231.47%	-66.06%	-18.05%
Net Income	-3.15M	-4.19M	-12.90M	-23.63M	-15.02M	-19.59M	-1.79M	-8.80M	-2.63M	-19.34M	-40.44M	-33.29M	-26.61M	-18.03M
Net Income Margin	-	-	-5288.93%	-	-4939.47%	-3075.04%	-15.10%	-1223.92%	-25.32%	-1272.94%	-902.21%	-201.29%	-82.70%	-35.52%
R&D	3.37M	3.12M	2.67M	5.28M	2.03M	4.71M	4.30M	2.50M	2.58M	579.00K	1.07M	2.29M	1.85M	1.57M
R&D as % of Total Revenue	-	-	1093.44%	-	667.43%	739.56%	36.19%	347.15%	24.83%	38.12%	23.91%	13.83%	5.74%	3.10%
Interest Expense	504.92K	1.27M	1.66M	1.87M	14.00K	17.00K	42.00K	2.00K	1.00K	8.00K	333.66K	1.04M	3.87M	7.57M
Interest Expense % of Total Revenue	-	-	678.28%	-	4.61%	2.67%	0.35%	0.28%	0.01%	0.53%	7.44%	6.26%	12.02%	14.93%

Balance Sheet

Currency: USD	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	4.45M	2.04M	1.00M	2.86M	52.38M	44.97M	43.38M	36.32M	32.53M	44.41M	22.07M	48.80M	57.42M	65.24M
Total Liabilities	7.70M	9.36M	19.29M	21.50M	3.99M	3.76M	2.95M	4.17M	2.25M	3.38M	16.65M	33.77M	58.74M	80.32M
Total Equity	-4.32M	-8.06M	-20.03M	-18.64M	48.40M	41.21M	40.43M	32.15M	30.28M	40.69M	5.43M	11.79M	-1.32M	-15.08M
Cash	4.00M	1.55M	477.00K	725.00K	20.98M	13.30M	9.78M	4.14M	2.94M	12.12M	2.82M	17.63M	7.02M	11.63M
Total Debt	4.84M	7.09M	8.46M	-	-	-	147.00K	20.00K	28.00K	156.00K	6.10M	25.80M	26.34M	30.15M
Net Debt	838.86K	5.54M	7.98M	-725.00K	-20.98M	-13.30M	-9.63M	-4.12M	-2.91M	-11.96M	3.28M	8.17M	19.33M	18.52M

Cash Flow

Currency: USD	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-2.90M	-3.27M	-3.34M	-4.18M	-10.26M	-16.15M	166.00K	-4.07M	-1.40M	-16.74M	-18.25M	-46.93M	-8.77M	-8.81M
Investing Cash Flow	-51.99K	-98.01K	-92.00K	-132.00K	-3.00M	-3.41M	-3.35M	-1.37M	-20.00K	-2.05M	-1.70M	-3.07M	-2.37M	-306.29K
Financing Cash Flow	3.44M	914.07K	2.36M	4.56M	33.51M	11.88M	-344.00K	-203.00K	-47.00K	27.58M	7.71M	62.77M	5.26M	13.75M
Capital Expenditure	0	0	92.00K	132.00K	3.17M	3.41M	3.35M	1.38M	23.00K	2.06M	1.90M	3.73M	34.27K	24.50K
Free Cash Flow	-2.90M	-3.27M	-3.43M	-4.32M	-13.43M	-19.56M	-3.52M	-5.45M	-1.42M	-18.80M	-20.14M	-50.65M	-8.80M	-8.83M
Dividends Paid	-	-	-	-	-	-	-	-	-	-	7.53M	-	-	-
FCF to OCF	100.00%	100.00%	102.75%	103.16%	130.96%	121.10%	-2122.29%	134.04%	101.64%	112.33%	110.39%	107.94%	100.39%	100.28%
Dividend Paid to FCF	-	-	-	-	-	-	-	-	-	-	-37.38%	-	-	-

Key Statistics & Ratios

Market Cap60.15M

Enterprise Value66.63M

Trailing P/E0.00

Forward P/E6.36

Price / Sales1.03

Price / Book76.33

EPS-0.01

Book Value-0.0106

Revenue (TTM)58.63M

Gross Profit (TTM)30.57M

EBITDA-4.43M

Profit Margin-17.69%

Operating Margin0.69%

Return on Equity-396.36%

Return on Assets-4.37%

Shares Outstanding1.07B

Shares Float413.37M

Beta1.73

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Dec 16, 202235:34
Mar 1, 2021779:757